Literature DB >> 19411164

Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery.

April Barbour1, Stephan Schmidt, W Robert Rout, Kfir Ben-David, Olaf Burkhardt, Hartmut Derendorf.   

Abstract

Antibiotic prophylaxis is intended to prevent postoperative wound infections, a major source of morbidity and mortality in surgical patients. Cefuroxime is a well-established second-generation cephalosporin that is given preoperatively in surgery units at a standard dose of 1.5 g. It is therefore important to determine whether cefuroxime distributes to the interstitial space fluid (ISF) of subcutaneous (s.c.) soft tissues, especially in obese patients who are at a higher risk of surgical site infections. In a single centre, prospective, open-label study, six morbidly obese patients [body mass index (BMI)> or =40] undergoing abdominal surgery received a single intravenous dose of 1.5 g cefuroxime within 1h of incision. Blood and microdialysis samples from the ISF of skeletal muscle and s.c. adipose tissue were collected before, throughout and after surgery for up to 6h post-dosing. Cefuroxime concentrations were determined by high-performance liquid chromatography-ultraviolet (HPLC-UV). Total peak concentrations in plasma (C(max)) (66.8+/-18.9 microg/mL) were higher than free C(max) levels in the ISF of muscle (60.1+/-15.2 microg/mL) and s.c. adipose tissue (39.2+/-26.4 microg/mL). Mean area under the free concentration-time curve ratios of muscle/total plasma (1.0+/-0.2) or s.c. adipose tissue/total plasma (0.6+/-0.5) indicate that cefuroxime distributes into the ISF of these tissues. In conclusion, the findings of this pilot study indicate that cefuroxime distributes into the ISF of muscle and s.c. adipose tissue of morbidly obese patients undergoing abdominal surgery. Concentrations in the ISF of soft tissues following a single 1.5 g dose may be high enough to prevent infections with Gram-positive organisms but may be insufficient to prevent infections with Gram-negative organisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411164     DOI: 10.1016/j.ijantimicag.2009.03.019

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  24 in total

1.  Continuous versus short-term infusion of cefuroxime: assessment of concept based on plasma, subcutaneous tissue, and bone pharmacokinetics in an animal model.

Authors:  Mikkel Tøttrup; Bo M Bibby; Tore F Hardlei; Mats Bue; Sigrid Kerrn-Jespersen; Kurt Fuursted; Kjeld Søballe; Hanne Birke-Sørensen
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

Review 2.  [Infection prevention by the anesthesia team].

Authors:  S Schulz-Stübner
Journal:  Anaesthesist       Date:  2013-01       Impact factor: 1.041

Review 3.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 4.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 5.  Role of microdialysis in pharmacokinetics and pharmacodynamics: current status and future directions.

Authors:  Francine Johansson Azeredo; Teresa Dalla Costa; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

Review 6.  Utility of Microdialysis in Infectious Disease Drug Development and Dose Optimization.

Authors:  Amelia N Deitchman; M Tobias Heinrichs; Vipada Khaowroongrueng; Satyawan B Jadhav; Hartmut Derendorf
Journal:  AAPS J       Date:  2016-12-09       Impact factor: 4.009

7.  Pharmacokinetics of Cefuroxime in Synovial Fluid.

Authors:  R Schwameis; S Syré; D Marhofer; A Appelt; D Burau; K Sarahrudi; C Kloft; M Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

8.  Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery.

Authors:  Alexandra Douglas; Andrew A Udy; Steven C Wallis; Paul Jarrett; Janine Stuart; Melissa Lassig-Smith; Renae Deans; Michael S Roberts; Kersi Taraporewalla; Jason Jenkins; Gregory Medley; Jeffrey Lipman; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

9.  Pharmacokinetic and Pharmacodynamic Evaluation of a Weight-Based Dosing Regimen of Cefoxitin for Perioperative Surgical Prophylaxis in Obese and Morbidly Obese Patients.

Authors:  Pierre Moine; Scott W Mueller; Jonathan A Schoen; Kevin B Rothchild; Douglas N Fish
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

10.  Antibiotic prophylaxis in bariatric surgery with continuous infusion of cefazolin: determination of concentration in adipose tissue.

Authors:  Rafael Anlicoara; Álvaro A B Ferraz; Kilma da P Coelho; José L de Lima Filho; Luciana T Siqueira; José G C de Araújo; Josemberg M Campos; Edmundo M Ferraz
Journal:  Obes Surg       Date:  2014-09       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.